Genome Beheer
Beheer criteriumcontroles 1/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Jisoo Pae
Algemeen directeur
n/a
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | 9.2yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 5.9yrs |
| Gemiddelde ambtstermijn bestuur | geen gegevens |
Recente managementupdates
Geen updates
Recent updates
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump
Nov 13
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump
Sep 06Is Genome (KOSDAQ:314130) A Risky Investment?
Jul 03Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump
May 27Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump
Apr 11Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?
Mar 08Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans
Mar 17CEO
Jisoo Pae
9.2yrs
Tenure
Mr. Jisoo Pae, M.D. is Director for Scioto Biosciences Inc. since 2022. He is Founder and Chief Executive Officer of Genome & Company since September 2015. Mr. Pae served as Psychiatrist at Seoul National...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder & CEO | 9.2yrs | geen gegevens | geen gegevens | |
| Chief Executive Officer | 2.7yrs | geen gegevens | geen gegevens | |
| Chief Executive Officer | 1.5yrs | geen gegevens | 0.032% ₩ 27.9m | |
| Founder & CTO | 9.5yrs | geen gegevens | geen gegevens | |
| Chief Financial Officer | no data | geen gegevens | geen gegevens |
5.9yrs
Gemiddelde duur
Ervaren management: Het managementteam van A314130 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.9 jaar).